Supply Chain/Logistics

Recognised with a Nobel Prize in 2020, CRISPR has opened the floodgates for a new era of gene editing therapies, promising to transform genetic disease treatments. With a well-established early field of genomics research, drug developers and researchers have been busy establishing the next-generation CRISPR toolkit, including Cas nucleases, base and prime editing technologies, and innovative delivery platforms. The CRISPR 2.0 Summit is devoted to showcasing only the latest and greatest innovations by uncovering how the next generation of CRISPR tools are radically enhancing efficacy, minimizing off-target effects and enabling efficient tissue-specific delivery to help you progress your program into and through the clinic.

From the earliest stages of characterization to the final steps of preparing for release and commercialization, our diverse program provides a comprehensive and unparalleled journey through end-to-end potency assay considerations. With a focus on practical insights, this summit equips you with the knowledge and expertise to ensure you’re prepared to excel in your role, which ultimately will bring better therapies to patients faster.

The Cell Therapy Analytical Development Summit Europe is the leading industry-defining forum in Europe made exclusively for analytical, CMC, QC, process development and regulatory experts. Next generation cell therapies are emerging as game changing treatments for cancer and beyond, but given their increasing complexities, developing robust, reliable, and in-depth analytical assays is critical to prove their safety and quality to the regulatory authorities.

New for 2022, take advantage of two tracks of content showcasing; Pre-IND & Early Clinical Development Exploring Assay Development for Best-in-Class Early-Stage Characterization; Establishing the Safety of Cell Therapy Products with Comprehensive Analytics Starting with the End-in-Mind: Considerations for Raw & Starting Material Analysis Optimizing Early-Stage Analytics to Bolster Speed to IND Submission & Phase 1 Launch Clinical Development & Commercialization; Improving Method Validation to Prepare for Successful Clinical Production; Approaching Later-Stage Analytical & Process Technology Transfers; Scaling Up from Clinical Development to Commercialization & Preparing for Release Optimizing Analytics During Manufacturing, Dealing with Process Changes

Join the CAR-TCR Summit Europe to connect with those trailblazing the next wave of CAR and TCR based approaches from preclinical development with in vivo engineering and regulatory fast-track strategies to streamlined analytics and automation to make CAR and TCR therapies better, and faster. Take advantage of cutting-edge innovation from global biopharma leaders in cell armouring, combination approaches and multiplexing gene engineering to improve cell durability and trafficking across allogeneic and solid tumor indications, and leave understanding the technical strategies to build automated, closed-system manufacturing processes to ensure vein to vein time is less than a week. Promising data-driven case studies outlining next generation product design, clinical trial set-up and manufacturing processes, this meeting is your go-to to comprehensively assess the emerging improvements of CAR and TCR based therapies across all emerging cell types including T, NK, macrophage, gamma delta T and iPSC.

After the explosive news that CAR-T therapies can now be considered curative, now is the time to unite with your industry, from the long-standing commercial giants to the trailblazing pioneers, and discover new strategies for everything from discovery to early phase development to commercialization. Gain end-to-end insights from both established thought leaders and the innovators bringing disruptive technologies from bench to bedside and from vein to vein. Across 3 conference days with 8 tracks, 13 Workshops, 1 Bootcamp and 1 Focus Day, 200+ CAR and TCR experts will lead you and 1,000 of your peers in discussions that will accelerate your pipeline and bring much-needed treatments to patients faster.

Allogeneic therapies are game-changing in the field of cell therapy, overcoming current critical barriers around cost, production, and accessibility currently faced with autologous, personalized treatments. With billions of pounds worth of investment seen in collaborations to advance the development of allogeneic CAR-T, NK, macrophage and iPSC-based therapies, the excitement in this space is explosive! Capitalizing on this “holy grail” approach at the 4th Allogeneic Cell Therapies Summit, the leading industry-focused meeting captured cutting-edge advances across pre-clinical development, translation, manufacturing, supply and storage, to accelerate the successful clinical translation of your allogeneic pipeline. This fast-evolving community compared and contrasted platform technology to improve durability and persistence, review the strategies for selecting gold-standard donor starting material, and learn about the latest developments in gene engineering and serve as the “off-the-shelf” ready-to-use therapeutic agents for large-scale clinical applications. Over 300 experts from pharma, biotech and leading academia united in Boston to collaborate and share lessons learned to streamline scalable manufacturing processes, define optimal cryopreservation conditions and define regulatory expectations to achieve the huge demand for these treatments.2022 showcased the work of Allogene, Atara Biotherapeutics, Cellectis, Celularity, ImmunityBio, and more, don’t miss out on the most important meeting of the cell therapy calendar in 2023.

Baird is delighted to host its annual Global Healthcare Conference. This conference brings institutional and private equity investors together with senior management from over 90 public and privately-held companies. The conference will feature companies across the following sectors: Biotechnology, Healthcare Supply Chain & Pharma Services, Healthcare Information Technology, Life Sciences & Diagnostics, Medical Technology and Facilities & Services. 

Advance your innovative biologics pipeline and elevate your engineering, targets and machine learning strategies – accelerating your path to the clinic and beyond.

Access new data & case studies from world-renowned speakers and companies across the entire landscape of oligonucleotides, peptides, mRNA, drug delivery and partnering strategies — from discovery to market, with an emphasis on the European region. Comprehensive CMC, analytical, manufacturing and regulatory strategies for both drug substance and drug product to accelerate oligonucleotide product development. Design oligonucleotides with better drug-like properties to accelerate your products to the clinic and to market. The latest preclinical and clinical updates to benchmark your research and improve your clinical efforts.